MAZE - NASDAQ

Maze Therapeutics, Inc.

MAZE·NASDAQ

$25.06

+3.2%

HealthcareBiotechnology

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.39B

EPS-3.0500

P/E Ratio-8.22

Earnings Date08/11/2026

0.00

Revenue

-100%

3Y-

5Y-

10Y-

-131.12M

Net Income

-351%

3Y+14.0%

5Y+14.0%

10Y+14.0%

-111.94M

Operating Cash Flow

-247%

3Y+13.0%

5Y+13.0%

10Y+13.0%

Maze Therapeutics, Inc. Profit Bridge

MAZE · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (2.40M)

Gross Profit-2.40M

Operating Expenses

Operating Expenses (140.50M)

Operating Income-142.90M

Other Income & Taxes

Interest Expense (0.00)

Other Income/Expense11.78M

Pretax Income-131.12M

Income Tax (0.00)

Net Income-131.12M

Net Income

-131.12M

Profitability Analysis

Maze Therapeutics, Inc. Income Statement

MAZE • NASDAQ

Maze Therapeutics, Inc. Income Statement	Dec 2025	Dec 2024	Dec 2023	Dec 2022
REVENUE
Revenue	0.0	167.5M	0.0	0.0
GROSS PROFIT
Cost of Revenue	(2.4M)	(0.0)	(0.0)	(0.0)
Gross Profit	-2.4M	167.5M	0.0	0.0
OPERATING INCOME
Operating Expenses	(140.5M)	(109.9M)	(98.6M)	(111M)
Selling, General & Administrative	(34.5M)	(26.4M)	(24.6M)	(22.8M)
Research & Development	(108.4M)	(83.5M)	(73.9M)	(88.2M)
Operating Income	-142.9M	57.6M	-98.6M	-111M
PRE-TAX INCOME
Net Interest Income	0.0	4.7M	2M	2M
Other Expenses	-2.4M	(0.0)	(0.0)	(0.0)
Total Other Income Expenses Net	11.8M	-4.2M	-1.9M	-3.9M
Income Before Tax	-131.1M	53.4M	-100.4M	-114.9M
NET INCOME
Income Tax Expense	(0.0)	(1.2M)	(0.0)	(0.0)
Net Income	-131.1M	52.2M	-100.4M	-114.9M

SEC Filings

MAZE - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 22, 2026	May 18, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 28, 2026	June 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 22, 2026	April 21, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 25, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 04, 2026	February 02, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 06, 2025	November 06, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 06, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 23 filings

Related Guides

Blog Categories

Continue your MAZE research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.